May 11, 2012

Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely active chroh's disease med primary endpoints of improvement in clinical remission in induction and maintenance phases.

Patients in the trial had failed at least one conventional therapy

OSAKA, Japan, May 11, 2012--- Takeda Pharmaceutical Company Limited (TSE:4502) today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn’s disease who have failed at least one conventional therapy, including TNFα antagonists. Many of the patients included in the study had failed two or more TNFα antagonists. Patients received a year of vedolizumab (MLN0002) or placebo treatment, starting with six weeks of induction therapy. In both phases of the trial, induction and maintenance, vedolizumab demonstrated statistically significant improvement in the primary endpoint of clinical remission compared to placebo. Additionally, vedolizumab provided a numerically higher rate of enhanced response, the other primary end point in the induction phase, although not statistically significant.

The most common adverse events (>10 percent) reported in both the vedolizumab arm and the placebo arm were: Crohn’s disease, arthralgia(joint pain), pyrexia(fever), nasopharyngitis(upper respiratory inflammation), headache, nausea, and abdominal pain.

"People living with moderately to severely active Crohn’s disease currently have few treatment options to help them manage their disease,” said Asit Parikh, M.D., Ph.D., Vice President, General Medicine (Gastrointestinal and Genitourinary), Takeda. “We are very excited about the results of this pivotal study and the potential it may hold for patients.”

Detailed results will be presented at an upcoming medical congress.

About Vedolizumab
Vedolizumab is an investigational humanized monoclonal antibody against α4β7 integrin, which is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis and Crohn’s disease.

About Crohn’s Disease
Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of the digestive tract, which can lead to abdominal pain, severe diarrhea and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Crohn's

Source:Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
disease can be both painful and debilitating, and sometimes may lead to life-threatening complications.

.pdfMay 11 2012Download the press release as PDF here